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SUSCEPTILBILTY PROFILE OF 288 Streptococcus
pneumoniae IN PATIENTS WITH CANCER (1998—
2002)
Safdar A*, Girgaway EA; The University of Texas M.D.
Anderson Cancer Center, Houston, Texas USA
BACKGROUND: The rise in community acquired
multidrug-resistant (MDR) Streptococcus pneumo-
niae has posed a serious challenge in the selec-
tion of appropriate antimicrobials for effective
prophylaxis and empiric-preemptive treatment of
susceptible patients with cancer. The frequency of
drug-resistance in clinical S. pneumoniae isolates
in patients receiving cancer therapy is not certain.
METHODS: All consecutive clinical isolates of S.
pneumoniae between January 1, 1998 and Decem-
ber 31, 2002 were analyzed. In vitro antimicrobial
susceptibility was performed according to NCCLS
guidelines; isolates with MICs >1g/ml for peni-
cillin (PCN) and ≥2g/ml for ceftriaxone (CTX)
were considered resistant (R).
RESULTS: During these 5 years, 141 (49%) of 288
total isolates were from blood culture samples;
110 (38%) respiratory samples included sputum,
bronchial wash and lavage. Susceptibility to peni-
cillin: 135 (47%) isolates were susceptible; in 151
non-susceptible S. pneumoniae, 68% (n = 102)
showed MIC in resistant range. Ceftriaxone suscep-
tibility: 91% (n = 262) were susceptible, and all
except one isolate, among 24 non-CTX suscepti-
ble S. pneumoniae were in the intermediate range
(n = 23). Yearly susceptibility trends of blood and
respiratory tract isolates are presented in Table be-
low.
CONCLUSIONS: In sharp contrast to drug-resistance
proﬁles of S. pneumoniae isolated from general
population, it was unexpected to ﬁnd that most
PCN non-susceptible strains for cancer patients
were resistant rather having intermediate suscep-
tibility. The decline in PCN resistance after the
year 2000 may in part reﬂect widespread use of
anti-streptococcal ﬂuoroquinolones in patients re-
ceiving treatment for cancer.
Specimens 1998 1999 2000 2001 2002
Blood N = 22 N = 37 N = 30 N = 32 N = 20
PCN-S 14 (64%) 15 (42%) 12 (40%) 18 (56%) 13 (65%)
PCN-I 0 1 (3%) 4 (13%) 6 (19%) 6 (30%)
PCN-R 8 (36%) 20 (56%) 14 (47%) 8 (25%) 1 (5%)
CTX-S 22 (100%) 37 (100%) 28 (93%) 26 (81%) 18 (90%)
CTX-I 0 0 2 (7%) 6 (19%) 2 (10%)
CTX-R 0 0 0 0 0
Respiratory N = 4 N = 13 N = 24 N = 27 N = 42
PCN-S 2 (50%) 5 (38%) 8 (33%) 13 (48%) 19 (46%)
PCN-I 0 1 (8%) 1 (4%) 9 (33%) 14 (34%)
PCN-R 2 (50%) 7 (54%) 15 (63%) 5 (19%) 8 (20%)
CTX-S 3/3 (100%) 12/12 (100%) 23 (96%) 23 (85%) 36 (86%)
CTX-I 0 0 1 (4%) 3 (11%) 6 (14%)
CTX-R 0 0 0 1 (4%) 0
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CHANGING SPECTURM OF POST-VIRAL PNEUMO-
NIA IN HOSPITALIZED PATIENTS WITH CANCER
Safar A*, Gonzalez O, Girgaway E; M.D. Anderson
Cancer Center, Houston, Texas 77030, USA
BACKGROUND: Inﬂuenza and respiratory syncy-
tial virus (RSV) infections are associated with
increased host’s susceptibility for secondary bac-
terial superinfections. Streptococcus pneumo-
niae, Staphylococcus aureus, including emerging
community-acquired methacillin-resistant strains,
and occasionally gram-negative bacilli may lead to
often serious, necrotizing pneumonia. We present
a changing spectrum of post-viral pulmonary su-
perinfection in our cancer patients during 2003.
RESULTS: Case 1. A 55-year-old neutropenic man
planned to undergo allogeneic hematopoietic stem
cell transplantation (HSCT) for CLL was respond-
ing favorably to ribavirin (2 gram daily) therapy
for RSV infection. A black facial lesion appeared 6
days post-transplant; in next 72 hours more than
15 pleomorphic ecthyma gangrenosum-like skin
lesions developed predominantly on his extrem-
ities, and the bilateral pleural-based pulmonary
inﬁltrates were highly suggestive of invasive fungal
disease. Blood cultures were sterile, albeit, Fusar-
ium spp. was isolated from bronchoalveolar lavage
and skin biopsy samples. Disseminated fusario-
sis was fatal in this patient with prior (∼4 week)
known nasopharyngeal Fusarium spp. colonization.
Case 2. A 4-year-old boy was being treated with
6-mercaptopurine and intrathecal baclofen for
refractory ALL and had responded favorably to ri-
mantadine plus oseltamivir for inﬂuenza infection.
A week after antiviral therapy was discontinued he
developed intermittent fever, hypoxemia, and new
multicentric pulmonary inﬁltrates. Tracheal aspi-
rate and blood culture reveal multidrug-resistant
Pseudomonas aeruginosa, which responded to com-
bination antimicrobial therapy. The P. aeruginosa
isolated during infection was pheotypically identi-
cal to the respiratory tract and tracheostomy site
colonizing strain (>4 weeks).
CONCLUSIONS: In immunosuppressed cancer pa-
tients with respiratory tract bacterial and/or fun-
gal colonization appears to alter the spectrum of
post-viral pulmonary superinfection.
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VANCOMYCIN-TOLERANT NON-ENTEROCOCCAL
GRAM-POSITIVE BACTEREMIA–—AN EMERGNG PHE-
NOMENON IN PATIENTS WITH CANCER
Safdar, A*, Rolston, KIV; M.D. Anderson Cancer Cen-
ter, Houston, Texas 77030, USA
BACKGROUND: Emergence of vancomycin-tolerant
gram-positive bacterial infection, poses yet an-
other treatment challenge. The impact of this
microbiological phenomenon on clinical out-
comes in the immunosuppressed cancer patients is
uncertain.
METHODS: Eight patients with non-enterococcal
gram-positive bloodstream infection who failed
to respond to vancomycin therapy were further
evaluated between 1993 and 2003. The organism
identiﬁcation and minimum inhibitory concentra-
tion (MIC) and minimum bactericidal concentration
(MBC) were performed at the Infectious Diseases
Research Laboratory at MDACC by methods out-
lined by National Committee on Clinical Laboratory
Standards (NCCLS).
RESULTS: Please refer to the Table below. All eight
patients had persistent bacteremia (≥72 h) after
institution of vancomycin. An indwelling intravas-
cular catheter (IC) was present in all, although
there was no clinical or microbiologic (IC tip cul-
ture) evidence of catheter infection. In patients 1
to 5, IC was removed ≤48 h after initial blood cul-
ture report became available. Similarly a secondary
focus of infection was not present. In 3 patients
(2, grade II-III, and 5, 6 Grade III-IV) oral mucosal
excoriation was present. In patients 1 to 4, gen-
tamicin (3 to 5mg/kg daily) plus rifampin (600mg
daily) and in patients 5 to 8, gentamicin alone lead
to a rapid (≤24 h) improvement as fevers abate
and blood cultures became sterile. No infection
recurrence occurred after discontinuation of 10 to
14 days of parenteral combination antimicrobial
therapy.
CONCLUSIONS: Vancomycin-tolerant gram-positive
bacteremia was seen sporadically during the
past decade at this comprehensive cancer cen-
ter. Awareness and prompt addition of adjuvant
aminoglycoside and/or rifampin was associated
with a favorable response in these high-risk cancer
patients.
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Pt. Age, sex Cancer ANC Microorganisms MIC MBC
1 55 y, F Ovarian, metastatic 300 Staphylococcus aureus 0.25 32
2 60 y, M AML 100 Staphylococcus aureus 1 64
3 42 y, F Breast, autologous SCT 450 Staphylococcus epidemidis 2 128
4 44 y, M Kaposi’s sarcoma, AIDS 300 Streptococcus, gp G 0.25 16
5 38 y, F Breast, autologous SCT <100 Streptococcus mitis 0.5 32
6 37 y, F AML <100 Streptococcus sanguis 0.12 32
7 44 y, M Sarcoma, metastatic 5000 Staphylococcus aureus 1 128
8 68 y, F Malignant melanoma 2000 Streptococcus gp G 0.12 32
NOTE. SCT: Stem cell transplant. AML: Acute myelogenous leukemia. MIC, and MBC values are given in
micrograms per milliliter. ANC: Absolute neutrophil count is given in cells/mm3.
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INFECTIONS IN PATIENTS WITH BILIARY OBSTRUC-
TION DUE TO PANCREATIC AND HEPATOBILIARY
CANCER: LONG TERM FOLLOW-UP
Costantini PE1, Rolston K2, Han XY2; 1Instituto de
Oncolog´ıa Angel H. Roffo, Universidad de Buenos
Aires, Argentina, 2M.D.Anderson Cancer Center,
Texas, USA
OBJECTIVE: To analyse episodes of fever, their
nature and management, in patients with hep-
atobiliary and pancreatic carcinoma with biliary
drainage, and to evaluate the correlation between
biliary isolates and other documented infections.
METHODS: A retrospective analysis of all episodes
of fever in 122 patients with hepatobiliary and pan-
creatic carcinoma that required biliary drainage,
between January 2000 and December 2001, was
performed. Episodes were subdivided into early
follow-up (since the insertion of the drainage until
surgery), post-operative (those occurring in the 30
days following surgery) and long term follow-up
(those that occurred thereafter).
RESULTS: Fever was the most frequent complication
in all the periods of follow-up, representing almost
always a documented infection. Cholangitis was
the most frequent infection during the early and
long-term follow-up. Ninety-nine patients under-
went surgery. 54% had one or more infection com-
plications, wound infection and abdominal collec-
tion being the most frequent. Febrile neutropenia
was an infrequent complication, requiring prompt
decompression through the insertion or change of
the stent or transhepatic catheter, and/or a short
course of antibiotics. In 24 cases there were paired
samples of biliary ﬂuid and a documented infec-
tion in 19 cases one or more of the biliary isolates
were also isolated from the documented infec-
tion Diverse species of Candida were frequently
isolated from biliary culture with no documented
increased risk of invasive fungal infection in these
patients.
CONCLUSION: In this population of patients with ob-
struction of the biliary tree fever was the most fre-
quent complication and almost always represented
a documented infection. There was a good correla-
tion between biliary isolates and other documented
infections.
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ANTIMICROBIAL RESISTANCE OF GRAM-NEGATIVE
BACTERIA IN A CANCER HOSPITAL
Volkova Z*, Kulaga, E, Sokolova V; N.N. Blokhin Can-
cer Research Center, Moscow, Russia
OBJECTIVE: The aim of the trial was studying the
rate of Pseudomonas aeruginosa resistance and rate
of ESBL — producers in cancer patients with noso-
comial infections in ICU compared with surgical de-
partments.
METHODS: Seventy one strains of P. Aeruginosa and
127 strains with a probability of ESBL producing iso-
lated in X-202—III-2003, were analyzed. Identiﬁca-
tion and susceptibility testing was performed with
ATB-Expressions (BioMerieux, France).
RESULTS: 27 of 71 (38.0%) of P. aeruginosa
strains were resistant to various antimicro-
bials. Resistance to ciproﬂoxacin was 68% in
SD vs. 87% in ICU (p>0.05); resistance to to-
bramycin, amkacin, gentamycin was 61%, 59%,
63% in SD vs. 87%, 81%, 87% in ICU, respec-
tively (p>0.05). Resistance to ceftazidime and
cefepim was 30% and 26% in SD vs. 71% and 57% in
ICU, respectively (p < 0.001—0.02). Resistance to
piperacillin-tazobactam and ticarcillin-clavulanate
was 33% and 44% in SD vs. 53% and 70% in ICH, re-
spectively, (p < 0.05), resistance to imipenem and
meropenem was 26% & 34% in SD vs. 71% and 73%
in ICU, respectively (p < 0.01—0.1). Eleven (15.5%)
of P. aeruginosa strains, isolated from different
patients were resistant to all tested antimicro-
bials (6 in ICU, 5 in SD). In ICU only 8 strains of
Enterobacteriaceae were isolated including E. coli
−4, Klebsiella spp. −3 and Proteus spp. −1 be-
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cause of non-fermenting rods prevalence. Among
119 strains from SD, E. coli was identiﬁed in 81
(68.1%), Klebsiella spp in 26 (21.8%), Proteus spp
were found in 1/8 (12.5%) strains in the ICU vs 2/12
(16.7%) in SD (p < 0.05). ESBL-producing Klebsiella
spp were found in 0/3 (0%) in ICU vs. 8/326 (31%)
in SD (p < 0.02), probably because of extensive
prescribing of III-generation cephalosporins in SD.
CONCLUSION: Isolation of ESBL — producers and
multi-resistant stains of P. aeruginosa requires
the development of rational approaches to em-
pirical treatment. Reduction of III generation
cephalosporins utilization is needed to avoid in-
crease of ESBL-producing Enterobacteriaceae.
068
CATHETER-RELATED VANCOMYCIN-RESISTANT
Enterococcus faecium BACTEREMIA: CINICAL
AND MOLECULAR EPIDEMIOLOGY
Raad II1, Hanna HA1, Boktour M1, Jabbour N1,
Hachem RY1, Darouiche RO2; 1The University of
Texas M.D. Anderson Cancer Center and 2Baylor
College of Medicine, Houston, Texas
To study the clinical and molecular epidemiol-
ogy of vancomycin resistant Enterococcus faecium
(VREF) organisms causing catheter-related bac-
teriemia (VREF-CRB), ten patients with VREF-CRB
were compared to 30 control patients with gas-
trointestinal colonization by VREF. Patients with
VREF-CRB were more likely to have required me-
chanical ventilation (<0.01), received total par-
enteral nutrition (P < 0.01), and had polyurethane
catheters (P < 0.01) inserted in the femoral vein
(P = 0.01). Using pulsed ﬁeld gel electrophoresis,
four of the ten VREF-CRB isolates were geneti-
cally indistinguishable, whereas only two of the
30 control VREF isolates displayed this same DNA
pattern (P = 0.03). In conclusion, VREF-CRB occurs
more frequently in patients who received total
parenteral nutrition, mechanical ventilation and
femoral catheters.
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BLOODSTREAM INFECTIONS SURVEILLANCE IN A
CANCER CENTER: A PROSPECTIVE LOOK AT CLINI-
CAL MICROBIOLOGY ASPECTS
Velasco E*, Byington R, Martins CAS, Schirmer
M, Dias LMC, Gonçalves VMSC; National Cancer
Institute; Hospital do Caˆncer, Rio de Janeiro,
Brazil
OBJECTIVE: To describe the frequency of occur-
rence and antimicrobial susceptibility proﬁles of
bloodstream infection (BSI) isolates at a tertiary
care referral oncology center.
METHODS: A prospective clinical and microbio-
logic surveillance study was conducted during a
26-month period and evaluated all consecutive in-
patients with malignancies or post-bone marrow
transplant with positive blood cultures.
RESULTS: The study enrolled 859 episodes of BSI
in 719 patients. There were 6.9 BSI episodes/1000
patient-days. Overall in-hospital mortality was 25%.
Median patients’ age was 43 years, 71% of episodes
occurred in patients above 18 years of age. Pa-
tients with underlying hematology malignancies
accounted for 38.2% of the episodes. An indwelling
CVC was present in 61% of episodes. BSI origin was
unknown in 27% of the episodes, associated with
other sites in 49.6% and catheter-related in 23.4%.
There were 638 concomitant infectious sites:
lungs, 28.4%; urinary tract, 14.8% and non-surgical
skin/soft tissue 9.7%. In total, 1039 microorgan-
isms were isolated within 48 h after the ﬁrst blood
culture: gram-negative rods (56%). Escherichia coli
and coagulase negative staphylococci. Klebsiella
pneumoniae (37.8%) and E. coli (8.9%) produced
ESBL. High rates of ceftazidime resistance were
detected among Acinetobacter spp. (40%) and En-
terobacter spp. (51.2%). E. coli and K. pneumoniae
were frequently isolated from hematology patients
and Enterobacter spp. from solid tumors patients.
E. coli, K. pneumoniae, and P. aeruginosa were
more often isolated from neutropenic than from
non-neutropenic patients. Oxacillin resistance was
detected in 18.7% of Staphylococcus aureus iso-
lates.
CONCLUSION: Continuous multidisciplinary surveil-
lance of BSIs is warranted in this high-risk group of
patients in order to develop strategies for antimi-
crobial resistance control and treatment of infec-
tious complications.
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A PROSPECTIVE EVALUATION OF THE EPIDEMIOL-
OGY, MICROBIOLOGY AND OUTCOME OF ADULT
SURGICAL CANCER PATIENTS WITH BLOODSTREAM
INFECTIONS
Velasco E*, Soares M, Byington R, Martins CAS,
Schirmer M, Dias LMC, Gonçalves VMSC; National
Cancer Institute; Hospital do Caˆncer, Rio de Janeiro,
Brazil
OBJECTIVE: To describe the epidemiology and mi-
crobiology of BSIs among adult surgical patients
and to determine independent factors inﬂuencing
in-hospital mortality in order to identify a subgroup
of surgical patients at higher risk of death.
METHODS: Prospective cohort study.
RESULTS: The study enrolled 112 consecutive
episodes of bloodstream infections (BSI) in adult
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surgical cancer patients during a 26-month period.
Median age was 64.5 years, and crude in-hospital
mortality 19.6%. The median duration from surgery
to the index blood culture was 11 days and from in-
dex blood culture to death was 4.5 days. Advanced
tumor disease was observed in 75% of patients,
36.6% of the patients were under intensive care
and 68.7% had a central venous catheter in-place
at the moment of BSI. Associated infected sites
were present in 57.1% of episodes. There were
328 noninfectious comorbidities. Poor performance
status, weight loss, hypoalbuminemia and ventila-
tory support corresponded to 67.4% of them. There
was a predominance of aerobic gram-negative
bacilli (62%), followed by gram-positive cocci
(26.6%) and fungi (9.3%). The observed mortal-
ity rate in these organism groups was similar
(23.6% vs. 15% vs. 28.6%, respectively; P = 0.44).
Main isolated organisms were Enterobacter spp.,
coagulase-negative staphylococci, Klebsiella spp.,
Acinetobacter spp. and fungi. Nonfermentative
strains predominated in patients with indwelling
catheters. Thirty-ﬁve pathogens (30.2%) were con-
sidered resistant. There was no signiﬁcant dif-
ference in the mortality rate between resistant
or non-resistant sentinel organisms (20% vs. 26%,
respectively; P = 0.49). Logistic regression anal-
ysis showed the presence of ≥4 comorbidities,
advanced tumor, thoracic surgery, catheters re-
tention and pulmonary inﬁltrates as independent
predictors of mortality.
CONCLUSIONS: Medical and infection control mea-
sures addressing some of variables amenable to in-
terventions might reduce the negative impact of
postoperative infectious morbidity and mortality.
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MALIGNANCY AND TUBERCULOSIS: DATA FROM
JULES BORDET INSTITUTE
Fanourgiakis P1*, Androulakis II1, Georgala A2,
Vekemans M2, Deshpande R2, Hennebert P2, Sk-
outelis A1, Aoun M2; 1Evangelismos Hospital, Athens
and 2Jules Bordet Institute, Brussels
INTRODUCTION: Active tuberculosis (TB) rate is
higher in cancer patients than in general popula-
tion. It is possible that TB is a predisposing factor
for cancer. It is well documented that malignancy
and/or its treatment are predisposing factors for
primary or reactivated TB. Malignancies and TB
may also have similar presentation and differential
diagnosis is not always easy.
OBJECTIVES: All TB cases in the past ten years were
retrospectively reviewed in order to estimate the
prevalence of TB between cancer patients of Jules
Bordet Institute in the era of the new therapeutic
modalities and compare it with that of population
of Brussels.
MATERIAL AND METHODS: Using the searching en-
gine of ‘‘Oribase’’, the electronic database of Jules
Bordet Institute, we identiﬁed all cases of active
TB hospitalized between July 1992 and July 2002.
Atypical mycobacteriosis, AIDS patients, and pa-
tients not proved to have cancer were excluded.
Active infection was considered to be present ei-
ther if cultures where positive for Mycobacterium
tuberculosis or if biopsy or autopsy revealed lesions
highly suggestive of active tuberculosis. Patient’s
medical charts were reviewed for clinical and lab-
oratory characteristics. Age, sex, clinical presen-
tation, past history of TB, underlying malignancy
and recent treatment, predisposing factors, anti TB
therapy and outcome, were recorded. The yearly
rate of TB in cancer patients of our Institute was
also calculated and compared with the overall rate
of TB in Brussels.
RESULTS: Thirty-two cancer patients with active TB
were identiﬁed. This corresponds to a mean annual
new case rate of all patients hospitalized in the In-
stitute of 117,6 new cases/100.000 patients/year.
The mean annual incidence of TB for the years
1993—2000 for Brussels was 35,93 cases/100.000
population/year. Three of the patients had prior
history of treated TB. TB occured in 11 patients
with lung cancer, 6 with ORL cancer, 4 with breast
cancer, 1 with esophageal cancer, 1 with osteosar-
coma, 1 with renal cell cancer, 1 with prostate
cancer, 1 with endometrial carcinoma, 1 with B-cell
non-Hodgkin lymphoma, 1 with MDS, 1 with CML,
1 with CLL, 1 with AML and in 1 patient with si-
multaneous occurrence of ORL and lung cancer. In
3 patients TB and malignancy were diagnosed si-
multaneously. 21 patients had been administered
an antineoplastic therapy (12 patients chemother-
apy, 4 radiotherapy and 5 both chemotherapy and
radiotherapy) whereas no antineoplastic or other
immunosupressive treatment was given in 11 cases.
Culture specimens were positive in 30 cases and
post mortem diagnosis was made in 2 cases. The
type of infection was as follows: 27 cases of pul-
monary TB, 2 cervical lymph TB, 1 mediastinal
tuberculous lymphadenopathy, 1 intestinal TB and
1 of miliary TB. Mortality due to TB was 6,25%
(autopsy proven).
CONCLUSIONS: Cancer patients treated in Jules
Bordet Institut between 08/1992—08/2002 had a
3,27 fold risk of active TB in comparison to the gen-
eral population in Brussels. Reactivation seems to
be the case for the great majority of our patients.
Latent tuberculosis represents an equilibrium state
between host and bacillus. Immune deﬁciency is
commonly implicated in the reactivation of TB. In
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these cases the malignancy per se (e.g. lympho-
proliferative disorders), or/and the therapeutic
agents are responsible for the immunosuppression.
Debilitation, cahexia and malnutrition, situations
commonly accompanying malignancies are also
well known to compromise the immune system.
Though their signiﬁcance is not well documented,
it seems reasonable that local factors may result
also in reactivation of TB. Radiation therapy may
be also a predisposing factor that impairs the im-
mune function and produces local damage. The
coexistence of these two entities may create major
diagnostic and therapeutic problems. So if TB or
malignancy is not diagnosed, this can be misdiag-
nosed as dissemination of the cancer or as failure
of antituberculous treatment.
